Physician profile
Camran Nezhat
NPI 1306902762
$13,120.60
in general payments reported to CMS, 2019-2025
10 companies · $1,684 in 2025
The $1,684 reported for 2025 was more than what 94% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $259 · 2021: $6,949 · 2022: $530 · 2023: $3,130 · 2024: $47.45 · 2025: $1,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,850 · Travel and Lodging: $1,482 · Food and Beverage: $529.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,850.00 |
| Travel and Lodging | $1,482.09 |
| Food and Beverage | $529.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicaroid, INC. | $9,381.63 | 2021-2023 | |
| Distalmotion US | $1,577.94 | 2025 | Dexter L6 Robot |
| Abbvie INC. | $1,413.64 | 2019-2025 | |
| Karl Storz Endoscopy-America | $224.14 | 2019 | |
| Myovant Sciences INC. | $173.34 | 2021-2022 | |
| Baxter Healthcare | $164.24 | 2019-2022 | |
| Medtronic, INC. | $90.10 | 2025 | |
| Aspira Women'S Health INC | $48.12 | 2022 | |
| Sumitomo Pharma America, INC. | $28.22 | 2024 | Myfembree |
| Pfizer INC. | $19.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Camran Nezhat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.